LeapFrog Intends to Part Ways with Its Indian Healthcare Investment Company
LeapFrog Investments, an emerging markets-focused private equity and impact investment firm, is considering exiting one of its Indian healthcare portfolio companies as part of its exit strategy from the Indian healthcare sector. The specific company targeted for this secondary-market exit has not been publicly named.
According to recent reports, LeapFrog is currently deploying its oversubscribed $1.15 billion Fund IV and is focusing on exits including secondary transactions to recycle capital. The firm has already exited other companies such as Goodlife Pharmacy in East Africa and Fincare Bank in India, but these are not referenced as part of the planned Indian secondary transaction.
LeapFrog's Indian healthcare portfolio includes firms such as Mumbai-based Ascent Meditech, Bengaluru-based MedGenome, Healthify, and Redcliffe Labs. However, no confirmation has been made as to which company is planned for sale.
Current members can log in to the website here to access exclusive curated articles for privileged insights. The terms of the potential exit, such as the buyer or the sale price, are not disclosed at this time.
It is important to note that the exact India portfolio company from LeapFrog Investments' portfolio that is being planned for sale has not been confirmed. Stay tuned for further updates on this developing story.
LeapFrog Investments, as part of its exit strategy from the Indian healthcare sector, is evaluating the possibility of selling one of its portfolio companies in the finance sector. The firm's current focus includes deploying capital from its Fund IV and pursuing exit opportunities, such as secondary transactions in businesses across industries.
